The G-6-PD, PGM1 and PGM3 phenotypes were examined in 16 different continuous human tumor cell lines (glioma and sarcoma) established in the Uppsala laboratory. The enzyme pattern did not deviate from that expected in a randomly drawn sample of tumors. There was no evidence of any cross-contamination between the lines or by HeLa cells.